Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor (Q46986653)
Jump to navigation
Jump to search
scientific article published in September 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor |
scientific article published in September 2013 |
Statements
1 reference
Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor (English)
1 reference
Mark Tirmenstein
1 reference
Thomas E Dorr
1 reference
Evan B Janovitz
1 reference
Deborah Hagan
1 reference
Lynn M Abell
1 reference
Joelle M Onorato
1 reference
Jean M Whaley
1 reference
Michael J Graziano
1 reference
Timothy P Reilly
1 reference
1 September 2013
1 reference
32
1 reference
336-350
1 reference
5
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference